LGVN Longeveron Inc.

NASDAQ

$2.81

Longeveron Inc. (LGVN) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $1.70 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -58.1% since its last earnings release on August 12, 2026.

Longeveron Reported In-line with Estimates

Wednesday, August 12, 2026 · 4:05 PM ET

3rd Quarter, Sep 2026

Wednesday · 4:05 PM ET

Earnings Whisper

-

vs ($1.70)

Rev est $770K

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $4.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.